DBVT
DBV Technologies S.A.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
4.76
P/S
942.28
EV/EBITDA
-3.91
DCF Value
$5.33
FCF Yield
-17.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
-1042.6%
Operating Margin
-20017.3%
Net Margin
-19549.8%
ROE
-189.5%
ROA
-63.0%
ROIC
-77.0%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $0.00 | $-44.8M | $-1.15 |
| FY 2025 | $0.00 | $-147.4M | $-5.30 |
| Q3 2025 | $0.00 | $-33.0M | $-1.60 |
| Q2 2025 | $0.00 | $-42.4M | $-1.70 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllLatest News
Company Info
Sector
Healthcare
Industry
—
Country
FR
Exchange
NASDAQ
Beta
-0.20
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults. The milk-induced company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of Immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA); Viaskin Egg, a pre-clinical stage product for the treatment of hen's egg allergy; and booster vaccine for Bordetella pertussis. Its other earlier stage research programs include a vaccine for the respiratory syncytial virus, as well as treatments for Crohn's disease, celiac disease, and type I diabetes. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.